1 / 5

Final Results From the Registry to Evaluate Novantrone (RENEW)

Final Results From the Registry to Evaluate Novantrone (RENEW). Victor Rivera, Bianca Weinstock-Guttman, Jacquie Beagan, Randy Bennett, Ahmad AL-Sabbagh, Fernando Dangond* September 2009 ECTRIMS Poster Award Presentation. *Dr. Dangond is an employee of EMD Serono, Inc. Background. RENEW.

vidal
Download Presentation

Final Results From the Registry to Evaluate Novantrone (RENEW)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Final Results From the Registry to Evaluate Novantrone (RENEW) Victor Rivera, Bianca Weinstock-Guttman, Jacquie Beagan, Randy Bennett, Ahmad AL-Sabbagh, Fernando Dangond* September 2009 ECTRIMS Poster Award Presentation *Dr. Dangond is an employee of EMD Serono, Inc.

  2. Background RENEW IV=intravenous *Novantrone was administered at the specified dosage until a cumulative dose of 140 mg/m2 was reached, a decision was made to discontinue therapy, or an adverse event precluded further therapy

  3. n=104 n=59 n=51 n=50 n=48 n=38 n=37 n=31 n=24 n=24 n=13 n=12 n=7 n=6 n=2 n=2 n=1 n=0 Number of Mitoxantrone Infusions Per Patient RENEW Mean infusions: n=6 Mean cumulative dose/patient: 69.8 mg/m2 3

  4. Cardiac Function, Amenorrhea, and Leukemia RENEW • Leukemia was reported in 3 patients† (0.6%) n represents the number of patients; CHF=congestive heart failure; LVEF=left ventricular ejection fraction *6 patients total experienced CHF during the treatment phase; values above equal 7 because 1 patient was included in both categories †One case deemed unrelated to mitoxantrone therapy

  5. Acknowledgments • A special thanks to • Victor Rivera, MD (Houston, TX) and Bianca Weinstock-Guttman, MD (Buffalo, NY) • RENEW Investigators

More Related